Press Releases

August 16, 2010

Bilcare posts net consolidated sales at Rs.308.54 cr; a growth of 29.38% for the quarter ended Q1 FY11

Click here to download PDF

Pune, 16 August 2010: Bilcare Ltd; service provider to the pharmaceutical companies spanning across their value chain from drug discovery to market posted its results for the quarter ended June 30th 2010.

The Consolidated Sales for the quarter ended June 30, 2010, thus stood at Rs. 308.54 crores, showing a growth of 29.38% over the corresponding quarter of the previous year; with the Consolidated EBITDA increasing to Rs.76.45 crores from Rs.55.77 crores, a growth of 37.08%.

The India Standalone Sales for the first quarter ended June 30, 2010 stood at Rs.154.85 crores as against Rs.128.51 crores in the same quarter of the previous year, showing a growth of 20.50%. This resulted in the higher EBITDA for India Standalone at Rs.44.79 crores from Rs.37.24 crores in the corresponding quarter of the previous year, showing a growth of 20.28%.

The Overseas business of the Company continued to show robust growth achieving sales of Rs.153.69 crores in the first quarter of the current year from Rs.109.96 crores in corresponding quarter of the previous year, a growth of 39.77%. The EBITDA from Overseas business grew to Rs.31.66 Crores from Rs.18.53 crores in the corresponding quarter of the previous year, a growth of 70.85%.

About Bilcare :

Bilcare is an internationally  integrated service provider to the global pharmaceutical industry offering innovative pharma packaging & research, global clinical trial supplies services and anti-counterfeiting technologies for the pharmaceuticals; while Bilcare Technologies under its nonClonableID™ offers identification , authentication and secure track-n-trace technologies Bilcare operates state-of-the-art manufacturing and research facilities in India, Singapore, USA, UK and has regional offices in Brazil, Germany, China and Australia. Bilcare provides solutions that address many of the industry's key concerns including the Five Key concerns - (5 C's) viz. counterfeit, compliance, communication, convenience and cost.

Press Contact:

Bilcare Research
Tel: +91 20 30257700
Email: corpcomm@bilcare.com

Click here to view Financial Result